Using claims-based measures to predict performance status score in patients with lung cancer

Cancer

Volumn 117, Issue 5, 2011, Pages 1038-1048

  Salloum, Ramzi G ^a,b   Smith, Thomas J ^c   Jensen, Gail A ^b   Lafata, Jennifer Elston ^a,d  

^a HENRY FORD HEALTH SYSTEM   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Automated claims; Chemotherapy; Lung cancer; Medical chart; Performance status; Tumor registry

Indexed keywords

ADULT; AGED; ARTICLE; AUTOMATION; CANCER REGISTRY; CANCER STAGING; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HEALTH INSURANCE; HUMAN; KARNOFSKY PERFORMANCE STATUS; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY AND SPECIFICITY;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEASIBILITY STUDIES; FEMALE; HUMANS; INSURANCE CLAIM REVIEW; KARNOFSKY PERFORMANCE STATUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; REGISTRIES; RESEARCH DESIGN; RETROSPECTIVE STUDIES;

EID: 79952035882     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25677     Document Type: Article

References (32)

1. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol. 1997;15:2996-3018.
2. National Cancer Institute: Physician Data Query Cancer Information Summaries. Bethesda, MD: National Cancer Institute; 2010. Available at: http://www.nci.nih.gov/cancer-info/pdq/treatment/non-small-cell-lung// healthprofessional/. Accessed May 11, 2010.
3. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol. 2004;22:330-353.
4. National Comprehensive Cancer Network and American Cancer Society. Lung Cancer: Treatment Guidelines for Patients. Version 1, December 2001. Fort Washington, PA: National Comprehensive Cancer Network; 2010. Available at: http://www.nccn.org. Accessed May 11, 2010.
5. Smith TJ, Penberthy L, Desch CE, et al. Differences in initial treatment patterns and outcomes of lung cancer in the elderly. Lung Cancer. 1995;13:235-252. (Pubitemid 26022990)
6. Bach PB, Cramer LD, Warren JL, Begg CB. Racial differences in the treatment of early-stage lung cancer. N Engl J Med. 1999;341:1198-1205. (Pubitemid 29480659)
7. Earle CC, Venditti LN, Neumann PJ, et al. Who gets chemotherapy for metastatic lung cancer? Chest. 2000;117:1239-1246.
8. Potosky AL, Saxman S, Wallace RB, Lynch CF. Population variations in the initial treatment of non-small-cell lung cancer. J Clin Oncol. 2004;22:3261-3268. (Pubitemid 41103681)
9. Hillner BE, McDonald MK, Desch CE, Smith TJ, Penberthy LT, Retchin SM. A comparison of patterns of care of non-small cell lung carcinoma patients in a younger and Medigap commercially insured cohort. Cancer. 1998;83:1930-1937. (Pubitemid 28503724)
10. Bradley CJ, Dahman B, Given CW. Treatment and survival differences in older Medicare patients with lung cancer as compared with those who are dually eligible for Medicare and Medicaid. J Clin Oncol. 2008;26:5067-5073.
11. Scott WJ, Howington J, Feigenberg S, Movsas B, Pisters K. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132(3 suppl):234S-242S.
12. Blagden SP, Charman SC, Sharples LD, Magee LR, Gilligan D. Performance status score: do patients and their oncologists agree? Br J Cancer. 2003;89:1022-1027.
13. Buccheri G, Ferrigno D, Tamburini M. Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer. 1996;32A:1135-1141.
14. Lilenbaum RC, Cashy J, Hensing TA, Young S, Cella D. Prevalence of poor performance status in lung cancer patients: implications for research. J Thorac Oncol. 2008;3: 125-129. (Pubitemid 351323185)
15. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987;40: 373-383. (Pubitemid 17055592)
16. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613-619.
17. Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol. 2001;154:854-864. (Pubitemid 33000813)
18. American Society of Health-System Pharmacists AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists; 2010.
19. Efron B, Gong G. A leisurely look at the bootstrap, the jackknife, and cross-validation. The Am Stat. 1983;37:36-48.
20. Lemeshow S, Hosmer DW Jr. A review of goodness of fit statistics for use in the development of logistic regression models. Am J Epidemiol. 1982;115:92-106. (Pubitemid 12205725)
21. Rodriguez E, Lilenbaum RC. New treatment strategies in patients with advanced non-small-cell lung cancer and performance status 2. Clin Lung Cancer. 2008;9:326-330.
22. Azzoli CG, Baker S Jr, Temin S, et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol. 2009;27:6251-6266.
23. Wright AA, Zhang B, Ray A, et al. Associations between end-of-life discussions, patient mental health, medical care near death, and caregiver bereavement adjustment. JAMA. 2008;300:1665-1673.
24. Zhang B, Wright AA, Huskamp HA, et al. Health care costs in the last week of life: associations with end-of-life conversations. Arch Intern Med. 2009;169:480-488.
25. Kelly K. Challenges in defining and identifying patients with non-small cell lung cancer and poor performance status. Semin Oncol. 2004;31(6 suppl 11):3-7. (Pubitemid 39600949)
26. Zimmermann C, Burman D, Bandukwala S, et al. Nurse and physician inter-rater agreement of 3 performance status measures in palliative care outpatients. Support Care Cancer. 2010;18:609-616.
27. Iezzoni LI. Risk adjustment for studying health care outcomes of people with disabilities. In: Iezzoni LI, ed. Risk Adjustment for Measuring Health Care Outcomes. 3rd ed. Ann Arbor, MI: Health Administration Press; 2003:363-382.
28. Earle CC, Neville BA, Landrum MB, Ayanian JZ, Block SD, Weeks JC. Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol. 2004;22:315-321. (Pubitemid 41095097)
29. Matsuyama R, Reddy S, Smith TJ. Why do patients choose chemotherapy near the end of life? A review of the perspective of those facing death from cancer. J Clin Oncol. 2006; 24:3490-3496. (Pubitemid 46638908)
30. Harrington SE, Smith TJ. The role of chemotherapy at the end of life: "when is enough, enough?." JAMA. 2008;299: 2667-2678.
31. Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol. 1991;9:1618-1626.
32. Iezzoni LI, Greenberg MS. Capturing and classifying functional status information in administrative databases. Health Care Financ Rev. 2003;24:61-76. (Pubitemid 36813991)